6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial

2013337 citationsJournal Article

Authors

Good health and well-being

Published in: The Lancet Oncology

Volume 14, Issue 8, pp. 741-748

Field-Weighted Citation Impact: 18.53